A detailed history of Royal Bank Of Canada transactions in Gossamer Bio, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 3,351 shares of GOSS stock, worth $2,345. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,351
Previous 3,613 7.25%
Holding current value
$2,345
Previous $3,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$0.79 - $1.25 $206 - $327
-262 Reduced 7.25%
3,351 $3,000
Q2 2024

Aug 14, 2024

BUY
$0.51 - $1.27 $236 - $588
463 Added 14.7%
3,613 $3,000
Q1 2024

Nov 05, 2024

SELL
$0.8 - $1.51 $370 - $699
-463 Reduced 12.81%
3,150 $3,000
Q1 2024

May 15, 2024

SELL
$0.8 - $1.51 $52 - $99
-66 Reduced 2.05%
3,150 $3,000
Q4 2023

Feb 14, 2024

BUY
$0.48 - $1.08 $31 - $71
66 Added 2.1%
3,216 $2,000
Q3 2023

Nov 14, 2023

SELL
$0.78 - $1.82 $167 - $391
-215 Reduced 6.39%
3,150 $2,000
Q2 2023

Aug 14, 2023

SELL
$0.98 - $1.53 $8,003 - $12,495
-8,167 Reduced 70.82%
3,365 $4,000
Q1 2023

May 15, 2023

SELL
$0.96 - $2.92 $5,485 - $16,684
-5,714 Reduced 33.13%
11,532 $14,000
Q4 2022

Feb 14, 2023

BUY
$1.74 - $12.87 $27,180 - $201,042
15,621 Added 961.29%
17,246 $37,000
Q3 2022

Nov 14, 2022

BUY
$7.21 - $14.88 $8,039 - $16,591
1,115 Added 218.63%
1,625 $19,000
Q2 2022

Aug 15, 2022

SELL
$5.97 - $9.97 $39,413 - $65,821
-6,602 Reduced 92.83%
510 $4,000
Q1 2022

May 16, 2022

SELL
$8.44 - $12.49 $38,300 - $56,679
-4,538 Reduced 38.95%
7,112 $61,000
Q4 2021

Feb 14, 2022

BUY
$10.12 - $14.07 $58,928 - $81,929
5,823 Added 99.93%
11,650 $132,000
Q3 2021

Nov 15, 2021

SELL
$7.25 - $13.23 $377,384 - $688,661
-52,053 Reduced 89.93%
5,827 $73,000
Q2 2021

Aug 16, 2021

BUY
$8.0 - $9.75 $463,040 - $564,330
57,880 New
57,880 $470,000

Others Institutions Holding GOSS

About Gossamer Bio, Inc.


  • Ticker GOSS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,954,000
  • Market Cap $65.8M
  • Description
  • Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony...
More about GOSS
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.